Skip to main content
Premium Trial:

Request an Annual Quote

Marc Lemaître

Link has appointed Marc Lemaître as chairman of the board. He takes over from Mick McLean, who is stepping down after nine years in the role. Lemaître currently works as an independent consultant, although he joined Link in 2015 as a non-executive director. He has also worked for Glen Research and served as CEO of Grindus America.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.